Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070006/S027

T-SPOT.TB TEST

Oxford Immunotec, Ltd. · Decision date Aug 4, 2025

FDA DECISIONP070006/S027

What did the FDA approve?

FDA records P070006/S027 as a supplement to PMA P070006, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 4, 2025.

FDA approval order statement

Approval for three changes to the T-Cell Select reagent kit: to change the concentration of one antibody reagent, to add an alternative supplier of both antibody reagents, and to extend the open container shelf life.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Aug 4, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P070006/S027
Regulatory pathway
PMA supplement
Product code
OJN
Decision code
APPR
Decision date
Aug 4, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Mycobacterium tuberculosis, Cell mediated immune response, enzyme-linked immunospot test.

Product code
OJN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P070006/S027 received

    Application receipt date recorded by FDA.

  2. P070006/S027 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P070006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070006

Product / regulatory recordCompanyPathwayDecision dateSource
T-SPOT.TB TestP070006/S028
Oxford Immunotec, Ltd.PMA supplementAug 4, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Oxford Immunotec, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
94c Innovation Dr., Milton Park, Abingdon Oxfordshire, OX14 4RZ

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records